Eli Lilly's Once-Weekly Insulin Onswik Receives FDA Approval for Type 2 Diabetes

The U.S. Food and Drug Administration (FDA) has approved Eli Lilly's Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin, for adults with type 2 diabetes. This new dosing schedule is designed to significantly reduce the number of annual injections compared to daily basal insulin. Eli Lilly anticipates the Onswik KwikPen will be available in the U.S. in the coming months.